题组负责人
周芳芳教授，国家杰青(2021)、长江青年学者(2017)
诚聘博士后，年薪四十万起可晋升；
诚聘副教授/研究员/副研究员，年薪四十万起可晋升；
研究方向：包括但不限于结构生物学、生物信息学、感染、免疫、肿瘤、信号转导等方向。
要求：工作自觉上进、有志于科学研究、有创新思维、甘于寂寞、敢于突破和探索、勇于创造。
有意向者请联系: zhoufangfang@suda.edu.cn
周芳芳2008年毕业于清华大学生物科学与技术系并获博士学位。2008-2013年在荷兰莱顿大学医学中心先后任职博士后、研究员。2013-2014年在荷兰莱顿大学医学中心任研究助理教授。2014年10月受聘苏州大学生物医学研究院特聘教授及博士生导师。周芳芳实验室致力于固有免疫响应的分子机制研究，取得了多项科研成果。独立开展工作后以通讯或共同通讯在国内外期刊如Cell (2024)、Nature Immunology（2017, 2018, 2022）、Nature Cell Biology（2012, 2021）、Molecular Cell（2013, 2020）、Nature Structural & Molecular Biology (2023)、Nature Communications (2017, 2022)、EMBO Journal (2022)、Trends in Biochemical Sciences (2013)、Advanced Materials（2021）、Cell Reports (2022)、Advanced Science (2019, 2020a, 2020b, 2021, 2022a, 2022b, 2023a, 2023b)、Signal Transduction and Targeted Therapy (2020a, 2020b, 2020c, 2021a, 2021b, 2022a, 2022b, 2022c, 2022d, 2023a, 2023b, 2023c, 2023d)、Molecular Cancer (2021)、Cell Death & Differentiation (2017)、Protein Cell (2014)、Cancer Research (2016)、Cell & Molecular Immunology (2020, 2021, 2022)、J Mol Cell Biol (2022, 2023)、MedComm (2022a, 2022b, 2023a, 2023b)、Molecular Biomedicine (2022a, 2022b)、Frontiers in Immunology (2021) 和MBoC（2011）等发表论文80余篇。
主要研究方向:
1. 固有免疫响应的分子机制和生理、病理调控；
2. 固有免疫防御病毒的机制及干预策略；
3. 肿瘤发生和逃脱固有免疫监视的分子机制；
代表性论文（*Corresponding author）:
1. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Zong Z, Xie F, et al., Zhou F*. Cell. 2024
2. TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. Ren J, Wang S, Zong Z, Pan T, et al., He X, Zhou F*, Zhang L*. Nature Communications. 2024
3. iProPhos: A Web-Based Interactive Platform for Integrated Proteome and Phosphoproteome Analysis. Zou J, Qin Z, Li R*, et al., Zhou F*, Zhang L*. Molecular Cellular Proteomics. 2024
4. TBK1: a new target for overcoming cancer immunotherapy resistance. Guan J, Zhang L*, Zhou F*. Science China Life Sciences. 2024
5. DeSUMOylation by SENP1 inhibits MAVS aggregation and antagonizes IRF3 activation. Dai T, Zhang L, Ran Y, et al., Lin S*, Zhang L*, Zhou F*. NatureStructure& Molecular Biology. 2023
6. Capturing Protein-Protein Interactions with Acidic Amino Acids Reactive Cross-Linkers. Liao QQ, Shu X, Sun W,MandapakaH, Xie F, Zhang Z, Dai T, Wang S, Zhao J, Jiang H, Zhang L, Lin J, Li SW,CoinI, Yang F, Peng J, Li K*, Wu H*, Zhou F*, Yang B*. Small. 2023
7. The role of TIA1 and TIAL1 in germinal center B cell function and survival. Wang Y, Liu J, Zhou F*. CellularMolecularImmunology. 2023
8. Biomolecular condensates:formationmechanisms, biological functions and therapeutic targets. Niu X, Zhang L, Wu Y, et al., Liu J*, Zhang L*, Zhou F*. MedComm. 2023
9. Deciphering dynamic changes of the aging transcriptome with COVID-19 progression and convalescence in the human blood. Li R, Zou J, Pei D, Pan T, et al., Chen Y*, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2023
10. The loss of epigenetic information: not only consequences but a cause of mammalian aging. Pan C, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2023
11. The fungal mycobiome: a new hallmark of cancer revealed by pan-cancer analyses. Z Zong, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2023
12. Motileciliaandmicrovillar: accomplices of SARS-CoV-2inpenetratingmucusbarrierandinfectingairwayepithelium. Su P, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2023
13. A review of gut microbiota-derived metabolites in tumor progression and cancer therapy. Yang Q, Wang B, Zheng Q, et al., Meng X*, Zhou F*, Zhang L*. Advanced Science. 2023
14. A review of extracellular vesicles in COVID-19 diagnosis, treatment and prevention. Su P, Wu Y, Xie F, Zeng Q, et al., Meng X*, Zhou F*, Zhang L*. Advanced Science. 2023
15. WNK1, a molecular crowding sensor, links phase separation to cellular physiological stress. Lan T, Zhou F*, Zhang L*. MedComm. 2023
16. Breast Cancer Cell-derived Extracellular Vesicles Promote CD8+ T cell Exhaustion via TGF-β type II receptor Signalling. Xie F, Zhou X, et al., Zhang L*, Zhou F*. Nature Communications. 2022
17. LPA maintains innate antiviral immunity in a pro-active state via STK38L-mediated IRF3 Ser303 phosphorylation. Wang S, et al., Zhang L*, Zhou F*. Cell Reports. 2022
18. Emerging implications of phase separation in cancer. Ren J, Zhang Z,ZongZ, Zhang L*, Zhou F*. Advanced Science. 2022
19. Wang Y，Fang X, Wang S, Wang B, Chu F, Zhang L*, Zhou F*. The role of O-GlcNAcylation in innate immunity and inflammation. Journal of MolecularCellBiology. 2022
20. Wang B, Zhang L, Zhou F*. Zhang L*. Potential mechanisms by which impairedketogenesislinksmetabolismto T-cell dysfunction in patients with severe COVID-19. Medcomm. 2022
21. DeactylationbySIRT1 enables liquid-liquid phase separation of IRF3/7 in innate antiviral immunity. Qin Z, Fang X, et al., Zhou F*, Zhang L*. Nature Immunology. 2022
22. IRF3 and IRF7 require SIRT1 for liquid-liquid phase separation andtransactivationofINF-I. Zhou F*, Zhang L*. Nature Immunology (Research Briefing). 2022
23. Targeting USP8 inhibits Cancer Progression and Prevents Extracellular-Vesicle TβRII-Induced Exhaustion of CD8+ T cells. Xie F, Zhou X, et al., Zhou F*, Zhang L*. EMBO Journal. 2022
24. Microbiotaintumors:fromunderstandingtoapplication. Xie Y, Xie F, Zhou X, et al., Zhang L*, Zhou F*. Advanced Science. 2022
25. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Fan Y, Li X, Zhang L, Wan S, Zhang L*, Zhou F*. Signal Transduction and Targeted Therapy. 2022
26. Cuproptosis: a new form of programmed cell death. Wang Y, Zhang L, Zhou F*. Cellular & Molecular Immunology. 2022
27. Guan J, Zhang L*, Zhou F*. PI3K-PANK4: a new target for de novo synthesis of coenzyme A. Molecular Biomedicine. 2022
28. Wei X, Xie F, Zhou X, Yan H, Liu T, Huang J*, Wang F*, Zhou F*, Zhang L*. Developments in the understanding of pyroptosis and its potential role in the treatment of inflammation and cancer. Cellular & Molecular Immunology. 2022
29. SUMOylation in Viral Replication and Antiviral Defense. Fan Y, Li X, Zhang L,et al., Zhang L*, Zhou F*. Advanced Science. 2022
30. STING, a critical contributor to SARS-CoV-2 immunopathology. Li H, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2022
31. Ferroptosis in cancer and cancer immunotherapy. Zhao L, Zhou X, Xie F, Zhang L, et al., Zhou F*, Chen J*, Zhang L*. Cancer Communications. 2022
32. Novel pyroptosis-independent functions of gasdermins. Qin Z, Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2022
33. Post-translational modifications in liquid-liquid phase separation: a comprehensive review. Li J, Zhang M, et al., Zhou F*, Zhang L*. Molecular Biomedicine. 2022
34. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Wang B, Zhang L, et al., Zhou F*, Zhang L*. Signal Transduction and Targeted Therapy. 2022
35. ADP-riboxanation: a new pyroptosis evasion strategy. Li H, Zhou F*, Zhang L*. J Mol Cell Biol. 2022
36. Wang S, Dai T, Qin Z, Pan T, et al., Zhou F*. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity via elevating MAVS activity. Nature Cell Biology. 2021
37. Xie F, Su P, Pan T et al., Zhang L*, Zhou F*. Engineering extracellular vesicles enriched with palmitoylated ACE2asCOVID-19 therapy. Advanced Materials. 2021
38. ISGylation in Innate Antiviral Immunity and Pathogen Defense Responses: A Review. Zhang M, et al., Zeng L*, Zhou F*. Front Cell Dev Biol. 2021
39. Wang B, Dai T, Ren J, et al., Zhou F*.Protein N-myristoylation: functions andmechanismsincontrolof innate immunity.Cellular & Molecular Immunology. 2021
40. Zong Z, Wei Y, Ren J, et al., Zhou F*. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer. 2021
41. Xie Y, Xie F, Zhou F*. Targeted anti-tumor immunotherapy using tumor infiltrating cells. Advanced Science. 2021
42. Dong Y, Dai T, Wang B, Zhou F*. The way of SARS-CoV-2 vaccine development:successandchallenges.Signal Transduction and Targeted Therapy.2021
43. Fan Y, Zhang L*, Zhou F*. cGAS-like receptors: new RNA sensors in Drosophila. Signal Transduction and Targeted Therapy.2021
44. Guo H, Zhou L, et al., Zhou F*. Promising immunotherapies against COVID-19. Advanced Therapeutics. 2021
45. Zhang Y, Qin Z, Sun W, Chu F, Zhou F*.Function of Protein S-Palmitoylation in Immunity and Immune-Related Diseases.Frontiers in Immunology. 2021
46. Gao L, Zhou F*.Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer.Frontiers in Cell and Developmental Biology. 2021
47. Zhang Z, Fang X, et al., Zhou F*. Acetylation-dependent deubiquitinase OTUD3 controls MAVS activation in innate antiviral immunity. Molecular Cell. 2020
48. Dong Y, Dai T, Wei Y, et al., Zheng M*, Zhou F*. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020
49. Zhou X, Xie F, Wang L, et al., Zhou F*. The function and clinical applicationofextracellular
vesicles in innate immune regulation. Cellular & Molecular Immunology. 2020
50. Wang S*, Zhou L, et al., Zhou F*. The Crosstalk Between Hippo-YAP PathwayandinnateImmunity. Frontiers in Immunology. 2020
51. Dong Y, Dai T, et al.,Zhou F*. Coronavirus in continuous flux: from SARS-CoV to SARS-CoV-2. Advanced Science. 2020
52. Zong Z, Zhang Z, et al.,Zhou F*. The functional deubiquitinating enzymes in control of innate antiviral immunity. Advanced Science. 2020
53. Jin K, et al., Zhou F*. An Effective Platform for Cancer Immunotherapy: Pooled Knockin Targeting for Genome Engineering Immunotherapies. Signal Transduction and Targeted Therapy. 2020
54. Cheng Z, Dai T, et al.,Zhou F*. The interaction between cGAS-STING pathway and pathogens. Signal Transduction and Targeted Therapy. 2020
55. Zhou L, Zhang Y, et al.,Zhou F*. A dual role of type I interferons in antitumor immunity. Advanced Biosystems. 2020
56. Xie F, Zhou X, Fang MY, et al.,Zhou F*. ExtracellularVesiclesinCancerImmune Microenvironment and Cancer Immunotherapy. Advanced Science. 2019
57. Gao L, Wang L, Dai T, Jin K, Zhang Z, et al.,Zhou F*, Zhang L*. Tumor-derived exosomes antagonize innate antiviral immunity. Nature Immunology. 2018
58. Wang S, et al., Zhang L*, Zhou F*. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through kinase-IKKe mediated phosphorylation. Nature Immunology. 2017
59. Zhang L*, Xie F, et al., Zhou F*. SUMO-triggered ubiquitination of NR4A1 controls macrophage cell death. CellDeathDifferentiation. 2017
60. Xie F, Jin K, Shao L, et al., Zhou F*, Zhang L*. FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. Nature Communications. 2017
61. Li Y, et al., Zhou F*, Zhang L*.c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/beta-Catenin/Axin2 Pathway. Cancer Research. 2016
62. Zhang J, et al., Zhang L*, Zhou F*. The regulation of TGF-β/SMAD signaling by protein deubiquitination. Protein Cell. 2014
63. Zhang L*,Zhou F*,tenDijkeP*. (2013) Signaling interplay betweentransforminggrowthfactor-β receptor and PI3K/AKT pathways in cancer. Trends in Biochemical Sciences. 2013
64. Zhang L,Zhou F*, et al., Ten Dijke P*. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Molecular Cell. 2013
65. Zhang L, Zhou F*, et al., ten Dijke P*. (2012) USP4 is regulated by Akt phosphorylation and directly deubiquitinates TGF-βtypeIreceptor. Nature Cell Biology. 2012
66. Zhang L,Zhou F*, et al., Fas-associated factor 1 antagonizes Wnt signaling by promoting β-catenin degradation. Molecular Biology of the Cell. 2011
E-mail: zhoufangfang@suda.edu.cn
Office：Dushulake703-B314
课题组成员
谢枫博士，特聘教授，博导，教育部青年长江学者
谢枫博士2017年毕业于浙江大学获博士学位，入选教育部青年长江学者、江苏省优秀青年，姑苏创新创业领军人才，江苏省双创博士和博新计划等人才项目。谢博士致力于研究蛋白翻译后修饰、细胞信号通路、外泌体及生物分子凝聚体在肿瘤转移与肿瘤免疫中的作用机制及治疗策略的开发。以第一或通讯作者（含共同）在Nature、Cell、Nature Communications等期刊上发表SCI论文25篇。个人主页: https://web.suda.edu.cn/xiefeng/. 邮箱: xiefeng@suda.edu.cn.
张正奎 特聘副教授
张正奎2018年毕业于浙江大学生命科学研究院并获博士学位，入选教育部第一批博士后海外引才专项，江苏省优青，国家博新人才，姑苏创新创业领军人才，先后在苏州大学、荷兰国家癌症研究所从事博士后研究工作， 2022年12月回国。张正奎博士致力于恶性肿瘤的发展、转移和免疫治疗耐受过程中肿瘤细胞与免疫细胞（CD8+ T细胞）的互作和调控，解析肿瘤免疫疗法耐受的机制。个人主页: https://web.suda.edu.cn/zzk1 . 邮箱: zkzhang@suda.edu.cn,办公室：703-B318.
代通博士，副教授
代通博士2020年毕业于苏州大学，获博士学位，2021年入选国家博新计划。致力于研究蛋白翻译后修饰和固有免疫响应的动态调控机制。以第一作者（含共同）在Nature Structural & Molecular Biology (2023)、Nature Cell Biology (2021)、Cell Host & Microbe (2018)、Nature Immunology (2018)等期刊上发表SCI论文10篇。个人主页: https://web.suda.edu.cn/dt2/。邮箱: tdai@suda.edu.cn。
褚峰 助理研究员
褚峰于2014年获得苏州大学发育生物学专业硕士学位，同年加入苏州大学周芳芳教授课题组担任技术员职位。
办公室：独墅湖校区703-B314
办公电话：(86)51265882491
E-mail: zhoufangfang@suda.edu.cn